Friday, March 1, 2013

ASH 2012: Dr. Tom Kipps ROR1

In this short final segment from my ASH 2012 interview, Dr. Kipps explains an exciting new target for CLL, ROR1 that seems to almost exclusively exist on cancer cells, making it an extremely attractive target for a vaccine, a monoclonal antibody, or CAR-T therapy.

Please excuse the bursts of static.

Soon I will be ASH 2012 interviews with Drs. Wierda on CAR-T,  Dr. Furman on his experience in the early trials with the TKIs, and an overview with Dr. Wiestner.

Pretty exciting stuff.

Labels: , , , , ,


Post a Comment

Subscribe to Post Comments [Atom]

<< Home